Estimates on HCV disease burden worldwide - Filling the gaps

Journal of Viral Hepatitis

Volumn 22, Issue s1, 2015, Pages 1-5

  Wedemeyer, H ^a   Dore, G J ^b   Ward, J W ^c  

^a Hannover Centre for Internal Medicine   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

diagnosis; disease burden; epidemiology; hepatitis C; hepatitis C virus; prevalence; strategy; sustained viral response; therapies; total infections; treatment

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; DRUG COST; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HEALTH; REIMBURSEMENT; VIRUS CARCINOGENESIS; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; COST OF ILLNESS; HEALTH; HEALTH CARE DELIVERY; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PREVALENCE; TREATMENT OUTCOME;

EID: 84920265713     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12371     Document Type: Article

References (18)

1. Lozano R, Naghavi M, Foreman K, et al,. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H,. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; Forthcoming.
3. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
5. Dusheiko G, Wedemeyer H,. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012; 61: 1647-1652.
6. Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA,. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology 2013; 58: 2142-2152.
7. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
8. Liang TJ, Ghany MG,. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917.
9. Dore GJ, Ward J, Thursz M,. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 2014; 21 (Suppl. 1): 1-4.
10. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H,. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014; 34: 1452-1463.
11. Bruggmann P, Berg T, Ovrehus AL, et al,. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl. 1): 5-33.
12. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 1): 34-59.
13. Wedemeyer H, Duberg AS, Buti M, et al,. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl. 1): 60-89.
14. Saraswat V, Norris S, de Knegt RJ, et al,. Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 2. J Viral Hepat 2015; 22 (Suppl. 1): 6-25.
15. Hatzakis A, Chulanov V, Gadano AC, et al,. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm-volume 2. J Viral Hepat 2015; 22 (Suppl. 1): 26-45.
16. Gane E, Kershenobich D, Seguin-Devaux C, et al,. Strategies to manage hepatitis C virus (HCV) infection disease burden-volume 2. J Viral Hepat 2015; 22 (Suppl. 1): 46-73.
17. Hickman M, Martin N, Vickerman P, Hutchinson S,. Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014; 21: e167-e168.
18. Razavi H, Bruggmann P, Wedemeyer H, Dore G,. Response to letter to the editor: strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014; 21: e169-e170.